CN116018402A - iPS细胞的品质改善剂、iPS细胞的制备方法、iPS细胞、及iPS细胞制备用组合物 - Google Patents

iPS细胞的品质改善剂、iPS细胞的制备方法、iPS细胞、及iPS细胞制备用组合物 Download PDF

Info

Publication number
CN116018402A
CN116018402A CN202180054397.0A CN202180054397A CN116018402A CN 116018402 A CN116018402 A CN 116018402A CN 202180054397 A CN202180054397 A CN 202180054397A CN 116018402 A CN116018402 A CN 116018402A
Authority
CN
China
Prior art keywords
gene
h1foo
cells
ips
ips cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180054397.0A
Other languages
English (en)
Chinese (zh)
Inventor
国富晃
福田惠一
汤浅慎介
朱亚峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keio School
ID Pharma Co Ltd
Kyoto University NUC
Heartseed Inc
Original Assignee
Keio School
ID Pharma Co Ltd
Kyoto University NUC
Heartseed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio School, ID Pharma Co Ltd, Kyoto University NUC, Heartseed Inc filed Critical Keio School
Publication of CN116018402A publication Critical patent/CN116018402A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180054397.0A 2020-09-04 2021-09-06 iPS细胞的品质改善剂、iPS细胞的制备方法、iPS细胞、及iPS细胞制备用组合物 Pending CN116018402A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-149447 2020-09-04
JP2020149447 2020-09-04
PCT/JP2021/032734 WO2022050419A1 (ja) 2020-09-04 2021-09-06 ｉＰＳ細胞の品質改善剤、ｉＰＳ細胞の製造方法、ｉＰＳ細胞、及びｉＰＳ細胞製造用組成物

Publications (1)

Publication Number Publication Date
CN116018402A true CN116018402A (zh) 2023-04-25

Family

ID=80491146

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180054397.0A Pending CN116018402A (zh) 2020-09-04 2021-09-06 iPS细胞的品质改善剂、iPS细胞的制备方法、iPS细胞、及iPS细胞制备用组合物

Country Status (5)

Country Link
US (1) US20230220025A1 (https=)
EP (1) EP4209593A4 (https=)
JP (1) JP7808298B2 (https=)
CN (1) CN116018402A (https=)
WO (1) WO2022050419A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107709553A (zh) * 2015-07-10 2018-02-16 心脏康复株式会社 高品质iPS细胞的制造方法
US20180195085A1 (en) * 2015-02-02 2018-07-12 Id Pharma Co., Ltd. Improved negative-strand rna viral vector

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0864645T3 (da) 1995-10-31 2005-10-24 Dnavec Research Inc Negativstrenget RNA-virusvektor med autonom replikeringsaktivitet
DK0863202T3 (da) 1995-11-01 2010-09-27 Dnavec Research Inc Rekombinant Sendai-virus
US6130313A (en) 1997-10-02 2000-10-10 Clontech Laboratories, Inc. Rapidly degrading GFP-fusion proteins
ATE399206T1 (de) 1999-05-18 2008-07-15 Dnavec Research Inc Ribonukleoproteinkomplex aus paramyxovirus
KR100739938B1 (ko) 1999-05-18 2007-07-16 가부시키가이샤 디나벡크 겐큐쇼 엔벨로프 유전자 결손 파라믹소과 바이러스 벡터
EP1211318B1 (en) 1999-09-06 2007-08-08 DNAVEC Research, Inc. Paramyxoviruses comprising a modified transcription start sequence
JPWO2003025570A1 (ja) 2001-09-18 2004-12-24 株式会社ディナベック研究所 粒子形成能が低下した（−）鎖ｒｎａウィルスベクターの検査方法および製造方法
JP4999330B2 (ja) 2004-01-22 2012-08-15 株式会社ディナベック研究所 サイトメガロウイルスエンハンサーおよびニワトリβ−アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖ＲＮＡウイルスベクターの製造方法
WO2006137517A1 (ja) 2005-06-24 2006-12-28 Dnavec Corporation 幼少個体への遺伝子導入用ベクター
JP4944781B2 (ja) 2005-09-15 2012-06-06 独立行政法人科学技術振興機構 テトラサイクリン系抗生物質によるタンパク質分解制御法
BRPI0619794B8 (pt) 2005-12-13 2022-06-14 Univ Kyoto Uso de um fator de reprogramação, agente para a preparação de uma célula-tronco pluripotente induzida a partir de uma célula somática e métodos para preparar uma célula- tronco pluripotente induzida método e para preparar uma célula somática e uso de células-tronco pluripotentes induzidas
CA2636600A1 (en) 2006-01-17 2007-07-26 Dnavec Corporation Novel protein expression system
KR20090052857A (ko) 2006-07-13 2009-05-26 디나벡크 가부시키가이샤 비복제형 파라믹소바이러스과 바이러스 벡터
US8173792B2 (en) 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
US9127256B2 (en) 2008-07-16 2015-09-08 Dnavec Corporation Method for production of reprogrammed cell using chromosomally unintegrated virus vector
JP5605658B2 (ja) 2009-04-30 2014-10-15 国立大学法人大阪大学 哺乳類細胞におけるタンパク質分解誘導方法
JP5696282B2 (ja) 2009-06-10 2015-04-08 国立大学法人京都大学 人工多能性幹細胞樹立効率改善剤
JP2011004674A (ja) 2009-06-26 2011-01-13 Fujitsu Ltd 誘導多能性幹細胞（ｉＰＳ細胞）の製造方法
CN104508131B (zh) * 2012-05-21 2018-11-23 加利福尼亚大学董事会 通过合成的自我复制的RNA形成人iPS细胞
JP2014217345A (ja) 2013-05-10 2014-11-20 学校法人 埼玉医科大学 人工多能性幹細胞製造用組成物、及び人工多能性幹細胞の製造方法
JP2014217344A (ja) 2013-05-10 2014-11-20 学校法人 埼玉医科大学 人工多能性幹細胞製造用組成物、及び人工多能性幹細胞の製造方法
KR102746901B1 (ko) * 2017-03-03 2024-12-26 옵시디안 테라퓨틱스, 인크. Cd19 조성물 및 면역요법을 위한 방법
WO2019093340A1 (ja) 2017-11-07 2019-05-16 国立大学法人京都大学 ナイーブ型多能性幹細胞からの原始内胚葉誘導方法
JP2020149447A (ja) 2019-03-14 2020-09-17 富士ゼロックス株式会社 表示情報生成装置及びプログラム
US12559730B2 (en) * 2020-01-16 2026-02-24 Riken Mutant KLF protein, and method for producing induced pluripotent stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180195085A1 (en) * 2015-02-02 2018-07-12 Id Pharma Co., Ltd. Improved negative-strand rna viral vector
CN107709553A (zh) * 2015-07-10 2018-02-16 心脏康复株式会社 高品质iPS细胞的制造方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AKIRA KUNITOMIDE等: "H1foo Has a Pivotal Role in Qualifying Induced Pluripotent Stem Cells", STEM CELL REPORTS, vol. 6, no. 6, 14 June 2016 (2016-06-14), XP055509242, DOI: 10.1016/j.stemcr.2016.04.015 *
LAURA A. BANASZYNSKIDE等: "A Rapid, Reversible, and Tunable Method to Regulate Protein Function in Living Cells Using Synthetic Small Molecules", CELL, vol. 126, no. 5, 8 September 2006 (2006-09-08), pages 3, XP093159707, DOI: 10.1016/j.cell.2006.07.025 *
PDB: "1BL4，FKBP MUTANT F36V COMPLEXED WITH REMODELED SYNTHETIC LIGAND", PDB, 2 September 1998 (1998-09-02) *

Also Published As

Publication number Publication date
JPWO2022050419A1 (https=) 2022-03-10
US20230220025A1 (en) 2023-07-13
EP4209593A4 (en) 2024-10-09
JP7808298B2 (ja) 2026-01-29
WO2022050419A1 (ja) 2022-03-10
EP4209593A1 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
KR101685209B1 (ko) 유도된 다능성 줄기 세포의 효율적인 확립 방법
EP2526189B1 (en) Method for improving induced pluripotent stem cell generation efficiency
KR101764100B1 (ko) 신규한 핵 재프로그래밍 물질
JP5765746B2 (ja) 効率的な人工多能性幹細胞の樹立方法
CN105916980B (zh) 用于改进诱导多能干细胞的效率的方法
JP6927578B2 (ja) 高品質なｉＰＳ細胞の製造方法
JP5773393B2 (ja) 効率的な人工多能性幹細胞の樹立方法
JP7808298B2 (ja) ｉＰＳ細胞の品質改善剤、ｉＰＳ細胞の製造方法、ｉＰＳ細胞、及びｉＰＳ細胞製造用組成物
HK40096086A (en) Quality improving agent for ips cells, method of producing ips cells, ips cells, and composition for producing ips cells
JP2014217344A (ja) 人工多能性幹細胞製造用組成物、及び人工多能性幹細胞の製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination